Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications.

Nakamura JL.

Expert Opin Ther Targets. 2007 Apr;11(4):463-72. Review.

PMID:
17373877
2.

Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.

Ye F, Gao Q, Xu T, Zeng L, Ou Y, Mao F, Wang H, He Y, Wang B, Yang Z, Guo D, Lei T.

J Neurooncol. 2009 Sep;94(2):183-94. doi: 10.1007/s11060-009-9836-1. Epub 2009 Mar 20.

PMID:
19300910
3.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
4.

Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas.

Krishnan S, Rao RD, James CD, Sarkaria JN.

Front Biosci. 2003 Jan 1;8:e1-13. Review.

PMID:
12456322
5.

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R.

Clin Cancer Res. 2008 Feb 15;14(4):957-60. doi: 10.1158/1078-0432.CCR-07-1810. Review.

6.

Therapeutic targeting of EGFR in malignant gliomas.

Ye F, Gao Q, Cai MJ.

Expert Opin Ther Targets. 2010 Mar;14(3):303-16. doi: 10.1517/14728221003598948. Review.

PMID:
20148717
7.
8.

The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.

Loew S, Schmidt U, Unterberg A, Halatsch ME.

Anticancer Agents Med Chem. 2009 Jul;9(6):703-15. Review.

PMID:
19601750
10.

Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications.

Nagane M, Lin H, Cavenee WK, Huang HJ.

Cancer Lett. 2001 Jan;162 Suppl:S17-S21. Review.

PMID:
11164186
11.

Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.

van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC.

Curr Cancer Drug Targets. 2009 Sep;9(6):748-60. Review.

PMID:
19754359
13.
14.

Signaling through the epidermal growth factor receptor during the development of malignancy.

Grandis JR, Sok JC.

Pharmacol Ther. 2004 Apr;102(1):37-46. Review.

PMID:
15056497
15.

Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.

Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S328-31. doi: 10.1016/j.apradiso.2009.03.030. Epub 2009 Mar 27.

PMID:
19467880
16.

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.

Longo SL, Padalino DJ, McGillis S, Petersen K, Schirok H, Politz O, Canute GW, Post DE.

Invest New Drugs. 2012 Dec;30(6):2161-72. doi: 10.1007/s10637-011-9784-4. Epub 2011 Dec 29.

PMID:
22203214
17.

Rational bases for the development of EGFR inhibitors for cancer treatment.

Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.

Int J Biochem Cell Biol. 2007;39(7-8):1416-31. Epub 2007 May 21. Review.

PMID:
17596994
18.

An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro.

Sugawa N, Ueda S, Nakagawa Y, Nishino H, Nosaka K, Iwashima A, Kurimoto M.

J Neurooncol. 1998 Sep;39(3):237-44.

PMID:
9821109
19.

Epidermal growth factor receptor: a promising target in solid tumours.

Laskin JJ, Sandler AB.

Cancer Treat Rev. 2004 Feb;30(1):1-17. Review.

PMID:
14766123
20.

The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB.

Clin Cancer Res. 2007 Mar 15;13(6):1911-25.

Items per page

Supplemental Content

Write to the Help Desk